根据2025年的试验数据,一种新的CAR-T疗法,Zamto-cel, 存活率翻了一番,并减少了无资格移植的老年淋巴瘤患者的副作用。 A new CAR-T therapy, zamto-cel, doubled survival and reduced side effects in older lymphoma patients ineligible for transplants, according to 2025 trial data.

来自2025年ASH年度大会的新数据表明,Zamtocabtagene autoleucel(zamto-cel),一种以CD20和CD19为对象的非冷冻性CAR-T疗法,大大改善了无资格进行干细胞移植的重症、高风险大B细胞淋巴瘤患者的化疗结果。 New data from the 2025 ASH Annual Meeting shows that zamtocabtagene autoleucel (zamto-cel), a non-cryopreserved CAR-T therapy targeting CD20 and CD19, significantly improved outcomes over chemoimmunotherapy in older, high-risk patients with relapsed or refractory large B-cell lymphoma ineligible for stem cell transplant. 在DALY 2-EU试验中,Zamto-cel将无事件生存(6.2对2.5个月)和无渐进生存(8.5对3.3个月)加倍,答复率较高,重毒性低。 In the DALY 2-EU trial, zamto-cel doubled event-free survival (6.2 vs. 2.5 months) and progression-free survival (8.5 vs. 3.3 months), with higher response rates and low severe toxicity. 其快速的为期12天的制造过程减少了过渡性治疗需求,为选择治疗有限的脆弱病人提供了有希望的选择。 Its rapid 12-day manufacturing process reduced bridging therapy needs, offering a promising option for vulnerable patients with limited treatment choices.